R-Pharm International, LLC
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| RPH-104 NCT05092776 |
P2 | Active, not recruiting | Familial Mediterranean Fever; FMF | 84 | 2025-01 |
| RPH-104 NCT05673902 |
P3 | Active, not recruiting | Idiopathic Recurrent Pericarditis | 17 | 2026-01 |
| Olokizumab NCT07670546 |
P3 | Active, not recruiting | Polymyalgia Rheumatica | 125 | 2026-04-10 |
| RS-113, 160 mg NCT07553988 |
P2 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 120 | 2026-05-14 |
| OKZ q4w NCT07517575 |
P2 | Recruiting | Juvenile Idiopathic Arthritis | 71 | 2026-09 |
| Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL) NCT06440746 |
P2/3 | Recruiting | Lung Diseases, Interstitial | 138 | 2027-04-09 (+10 mo) |
| Goflikicept NCT07625384 |
P3 | Not yet recruiting | Still Disease | 52 | 2027-12-14 |
| RPH-104 NCT05190991 |
P2 | Recruiting | Familial Mediterranean Fever; FMF | 60 | 2028-12 (+71 mo) |